We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

80 hedge funds and large institutions have $308M invested in Xenon Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 27 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

1% more funds holding

Funds holding: 79 → 80 (+1)

0.16% less ownership

Funds ownership: 79.95% → 79.79% (-0.16%)

12% less capital invested

Capital invested by funds: $351M → $308M (-$42.7M)

41% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 27

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
80
Holders Change
+1
Holders Change %
+1.27%
% of All Funds
1.61%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
6
Increased
16
Reduced
27
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.01M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$5M
3
SCM
Soleus Capital Management
Connecticut
+$2.93M
4
GIM
Granahan Investment Management
Massachusetts
+$561K
5
Goldman Sachs
Goldman Sachs
New York
+$385K

Top Sellers

1
ACP
Acuta Capital Partners
California
-$2.56M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.5M
3
Renaissance Technologies
Renaissance Technologies
New York
-$1.55M
4
PHP
Parkman Healthcare Partners
Connecticut
-$1.48M
5
JP Morgan Chase
JP Morgan Chase
New York
-$1.21M
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$38.7M -$206K -17,505 -0.5%
ACA
2
Avoro Capital Advisors
New York
$31M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$29.1M +$5.01M +425,566 +19%
O
4
OrbiMed
New York
$27.7M – – –
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$27.1M +$5M +425,000 +21%
EAM
6
Eventide Asset Management
Massachusetts
$14.1M – – –
Capital International Investors
7
Capital International Investors
California
$11.7M – – –
NMC
8
NEA Management Company
Maryland
$11M – – –
Capital World Investors
9
Capital World Investors
California
$10.7M – – –
Renaissance Technologies
10
Renaissance Technologies
New York
$10M -$1.55M -132,000 -13%
BBA
11
Baker Bros. Advisors
New York
$8.42M -$456K -38,794 -5%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$8.27M -$563K -47,886 -6%
BC
13
Boxer Capital
California
$6.64M – – –
RSCM
14
Rock Springs Capital Management
Maryland
$5.71M – – –
SCM
15
Soleus Capital Management
Connecticut
$5.54M +$2.93M +249,367 +99%
PHP
16
Parkman Healthcare Partners
Connecticut
$5.15M -$1.48M -125,442 -21%
DCM
17
Driehaus Capital Management
Illinois
$5M -$152K -12,926 -3%
Point72 Asset Management
18
Point72 Asset Management
Connecticut
$4.95M -$2.5M -212,343 -32%
UBS AM
19
UBS AM
Illinois
$4.08M +$41.4K +3,522 +1%
DCM
20
DAFNA Capital Management
California
$3.84M – – –
GTC
21
Ghost Tree Capital
New York
$3.6M – – –
Citadel Advisors
22
Citadel Advisors
Florida
$3.45M -$925K -78,578 -20%
ACP
23
Acuta Capital Partners
California
$3.32M -$2.56M -217,500 -42%
IC
24
Ikarian Capital
Texas
$2.47M -$882K -75,000 -25%
D.E. Shaw & Co
25
D.E. Shaw & Co
New York
$2.13M -$204K -17,305 -8%
1
2 3 4

XENE Hedge Fund Activity: Q3 2020 in Review

80 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q3 2020, worth a combined $308M — down 12% from $351M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new XENE positions and 5 closed out — a net gain of 1 holder — while 16 added to existing stakes and 27 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $5.01M. The largest seller was Acuta Capital Partners, cutting an estimated $2.56M.

  • 80 institutional investors held Xenon Pharmaceuticals (XENE) as of Q3 2020, up from 79 in Q2 2020.
  • Funds reported $308M of Xenon Pharmaceuticals stock for Q3 2020, down 12% quarter-over-quarter.
  • 6 funds opened new Xenon Pharmaceuticals positions in Q3 2020 and 5 closed out, a net change of +1 holder.
  • The largest Xenon Pharmaceuticals buyer in Q3 2020 was Fidelity Investments, an estimated $5.01M added.
  • The largest Xenon Pharmaceuticals seller in Q3 2020 was Acuta Capital Partners, an estimated $2.56M sold.

Based on aggregated 13F filings for Q3 2020.